Join us tomorrow at 8:00am ET for Aquestive’s virtual #InvestorDay for to hear how we’re working to harness the therapeutic potential of #epinephrine through our Adrenaverse™ platform to provide future treatments across multiple disease states, starting with Anaphylm™ (epinephrine) #sublingual film and AQST-108 (epinephrine) topical gel. The event will also feature presentations from Aquestive leadership and Dr. David Farrar, Assoc. Professor, Immunology/Molecular Biology, UT Southwestern Medical Center. Register here: https://bit.ly/4gp71pk. #AQST
On September 27th, Aquestive will host a virtual Investor Day at 8:00 am ET to discuss pipeline updates related to our Adrenaverse™ #epinephrine prodrug platform, including Anaphylm™ (epinephrine) #Sublingual Film and AQST-108 (epinephrine) Topical Gel. The event will feature presentations by Aquestive's management team and by David Farrar PhD, Associate Professor, Immunology/Molecular Biology, UT Southwestern Medical Center. Register here: https://bit.ly/4gp71pk, and read our full press release, linked in comments below, to learn more. #AQST #pharmaceuticalinnovation #investorday